0001209191-22-047031.txt : 20220822
0001209191-22-047031.hdr.sgml : 20220822
20220822164110
ACCESSION NUMBER: 0001209191-22-047031
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220818
FILED AS OF DATE: 20220822
DATE AS OF CHANGE: 20220822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUGGENHIME ANDREW
CENTRAL INDEX KEY: 0001230724
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 221184210
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-18
0
0001649094
Vaxcyte, Inc.
PCVX
0001230724
GUGGENHIME ANDREW
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
0
1
0
0
President and CFO
Common Stock
2022-08-18
4
M
0
3100
5.35
A
45287
D
Common Stock
2022-08-18
4
S
0
2551
25.13
D
42736
D
Common Stock
2022-08-18
4
S
0
549
25.89
D
42187
D
Stock Option (right to buy)
5.35
2022-08-18
4
M
0
3100
0.00
D
2030-05-11
Common Stock
3100
493618
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted-average price. The shares were sold at prices ranging from $24.615 to $25.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $25.71 to $26.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
2022-08-22